Key Takeaways
- On April 28, 2026, Gilead Sciences finalized its $7.8 billion purchase of Arcellx, securing complete ownership of anito-cel, a CAR T-cell treatment for multiple myeloma.
- The stock is revisiting a critical breakout level from an 11-year cup-with-handle formation at $123.47, with one analyst projecting a year-end price of $173—representing potential upside of 35%.
- Despite falling 8% in April, GILD has climbed 22% year-over-year and currently trades near $128.
- Technical indicators show GILD’s RSI at 27, the most oversold reading in over a year, with the 200-day moving average providing nearby support.
- While the acquisition will negatively impact 2026 GAAP and non-GAAP diluted EPS by $5.57 to $5.67, the deal is anticipated to contribute positively to earnings starting in 2028, contingent on regulatory approval.
Gilead Sciences wrapped up its Arcellx acquisition on April 28, offering shareholders $115 cash per share alongside a contingent value right worth $5 per share. The transaction’s total implied equity value reached roughly $7.8 billion.
This acquisition grants Gilead complete control over anitocabtagene autoleucel (anito-cel), an experimental BCMA-targeted CAR T-cell treatment designed for multiple myeloma patients. The two companies had previously maintained a partnership arrangement through Kite, Gilead’s cellular therapy division.
By taking full ownership of Arcellx, Gilead removes ongoing profit-sharing arrangements, milestone payments, and royalty commitments from the equation. This strategic shift enables the pharmaceutical giant to accelerate development timelines and commercialization strategies.
The $5 contingent value right will only trigger if anito-cel achieves cumulative worldwide net sales of at least $6 billion between its market launch and December 31, 2029. While ambitious, this threshold demonstrates Gilead’s bullish outlook on the treatment’s revenue potential.
Cindy Perettie, who leads Gilead’s Kite division, emphasized that priorities now shift toward “executing with speed and discipline” while preparing to deliver anito-cel to patients. The integration will bring Arcellx’s workforce and its proprietary D-Domain BCMA binder platform into Kite’s existing manufacturing and regulatory framework.
Financially, the transaction will decrease Gilead’s 2026 diluted EPS by $5.57 to $5.67 on both GAAP and non-GAAP bases. When excluding acquired in-process research and development costs, the deal shows modest dilution through 2027, shifting to earnings accretion in 2028 and beyond—provided anito-cel receives FDA clearance.
Following the merger’s finalization, Arcellx common stock will exit from the Nasdaq Global Select Market.
Chart Analysis
From a technical perspective, GILD has reached a compelling inflection point. The shares are now retesting a breakout from an 11-year cup-with-handle pattern at the $123.47 pivot—a formation that originated from bearish candlestick patterns observed in mid-2015.
Historically, breakouts from extended base patterns demonstrate higher reliability, making this current test particularly noteworthy. The stock’s Relative Strength Index has plunged to 27, marking the lowest reading in at least twelve months and indicating deeply oversold territory. The 200-day simple moving average sits just below current prices and previously provided support during May and October of last year.
GILD has posted declines in eight out of the past ten weeks, with April alone showing an 8% drop. Notably, both March and April’s selloffs occurred on below-average volume, which technical traders often interpret as a positive divergence.
Industry Landscape
The SPDR S&P Biotech ETF has delivered a 9% return in 2026, outperforming the struggling healthcare sector, which has dropped 7% and ranks as the poorest performer among the 11 primary S&P sectors. Meanwhile, the iShares Biotechnology ETF, which counts Gilead as its top holding at nearly 8% of net assets, has barely moved with less than 1% gains year-to-date.
GILD itself shows a 4% advance in 2026 and a robust 22% increase over the trailing twelve months, notwithstanding the recent correction. One technical strategist has established a $173 price objective for year-end, suggesting 35% appreciation from the current $128 trading level. This optimistic scenario remains valid provided the stock maintains support above $118.
Gilead concluded its tender offer for Arcellx on April 28, with submitted shares accounting for approximately 77.2% of Arcellx’s total outstanding equity.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
